Plenary Session 1: Novel Insights in the Biology of Allergic Responses in Immunotherapy
1-1: Personalized Medicine in Allergy and Asthma
1-1: Personalized Medicine in Allergy and Asthma
Plenary Session 1: Novel Insights in the Biology of Allergic Responses in Immunotherapy
1-2: Biologic Basis of the Allergic Response
1-2: Biologic Basis of the Allergic Response
Plenary Session 1: Novel Insights in the Biology of Allergic Responses in Immunotherapy
1-3: Overview of Allergen Immunotherapy and Tolerance
1-3: Overview of Allergen Immunotherapy and Tolerance
Plenary Session 1: Novel Insights in the Biology of Allergic Responses in Immunotherapy
1-4: New Treatments for Allergen Immunotherapy
1-4: New Treatments for Allergen Immunotherapy
Biologics Track 1: Overview and Newer Uses of Anti-IgE
1-5: The Role of IgE-Receptors in Airway Inflammation and Remodelling
1-5: The Role of IgE-Receptors in Airway Inflammation and Remodelling
Biologics Track 1: Overview and Newer Uses of Anti-IgE
1-6: New Strategies with Anti-IgE in Allergic Diseases
1-6: New Strategies with Anti-IgE in Allergic Diseases
Biologics Track 1: Overview and Newer Uses of Anti-IgE
1-7: Oral Immunotherapy and Anti-IgE Antibody-Adjunctive Treatment for Food Allergy
1-7: Oral Immunotherapy and Anti-IgE Antibody-Adjunctive Treatment for Food Allergy
Immunotherapy Track 1: Overview of Immunotherapy
1-9: Historical Perspective and Current Standards in Immunotherapy: Challenges and Unmet Needs
1-9: Historical Perspective and Current Standards in Immunotherapy: Challenges and Unmet Needs
Immunotherapy Track 1: Overview of Immunotherapy
1-10: Subcutaneous Immunotherapy: Perspectives of Treatment Practices in the US and Europe
1-10: Subcutaneous Immunotherapy: Perspectives of Treatment Practices in the US and Europe
Immunotherapy Track 1: Overview of Immunotherapy
1-11: Speaking the Same Language: Grading System for Subcutaneous Immunotherapy Systemic Reaction
1-11: Speaking the Same Language: Grading System for Subcutaneous Immunotherapy Systemic Reaction
Immunotherapy Track 1: Overview of Immunotherapy
1-12: Management of Anaphylaxis during Immunotherapy
1-12: Management of Anaphylaxis during Immunotherapy
Biologics Track 2: Novel Anti-Cytokines
1-13: IL-1 and IL-17 Cytokine Families: New Targets for Allergy Related Disorders
1-13: IL-1 and IL-17 Cytokine Families: New Targets for Allergy Related Disorders
Immunotherapy Track 2: Sublingual Immunotherapy
1-16: Recommendations for Appropriate Sublingual Immunotherapy Clinical Trials
1-16: Recommendations for Appropriate Sublingual Immunotherapy Clinical Trials
Immunotherapy Track 2: Sublingual Immunotherapy
1-17: Current Status of Sublingual Immunotherapy in the United States
1-17: Current Status of Sublingual Immunotherapy in the United States
Immunotherapy Track 2: Sublingual Immunotherapy
1-18: WAO Position Paper Update on Sublingual Immunotherapy
1-18: WAO Position Paper Update on Sublingual Immunotherapy
Immunotherapy Track 3: Immunotherapy Targets for Food
1-19: Use of Allergen Components: A New Era in Allergology
1-19: Use of Allergen Components: A New Era in Allergology
Immunotherapy Track 3: Immunotherapy Targets for Food
1-20: Oral and Sublingual Immunotherapy for Food Allergy
1-20: Oral and Sublingual Immunotherapy for Food Allergy
Immunotherapy Track 3: Immunotherapy Targets for Food
1-21: Epicutaneous Immunotherapy for Food Allergy
1-21: Epicutaneous Immunotherapy for Food Allergy
Biologics Track 3: New Directions in Immunotherapy
1-22: Identification of Therapeutic Epitopes from Allergens
1-22: Identification of Therapeutic Epitopes from Allergens
Biologics Track 3: New Directions in Immunotherapy
1-23: Specific Immunoregulatory Epitopes in the Treatment of Allergic Disease
1-23: Specific Immunoregulatory Epitopes in the Treatment of Allergic Disease
Biologics Track 4: Critical Novel Molecules for Allergic Diseases
2-1: Role of Thymic Stromal Lymphopoietin (TSLP) in Allergic Responses
2-1: Role of Thymic Stromal Lymphopoietin (TSLP) in Allergic Responses
Biologics Track 4: Critical Novel Molecules for Allergic Diseases
2-3: Advances in Synthetic Peptide Immuno-Regulatory Epitopes
2-3: Advances in Synthetic Peptide Immuno-Regulatory Epitopes
Immunotherapy Track 4: Other Novel Approaches to Immunotherapy
2-6: Passive Immunization with Allergen-Specific IgG Antibodies for the Treatment and Prevention of Allergy
2-6: Passive Immunization with Allergen-Specific IgG Antibodies for the Treatment and Prevention of Allergy
Biologics Track 5: Biomarkers, Biosimilars and Selection of Patients
2-7: The Use of Biomarkers in Asthma Clinical Research Trials
2-7: The Use of Biomarkers in Asthma Clinical Research Trials
Biologics Track 5: Biomarkers, Biosimilars and Selection of Patients
2-8: Inner City Asthma and Anti-IgE
2-8: Inner City Asthma and Anti-IgE
Immunotherapy Track 5: Social Consequences and Evidence Based Medicine and Immunotherapy
2-12: Selection of Patients for Sublingual versus Subcutaneous Immunotherapy
2-12: Selection of Patients for Sublingual versus Subcutaneous Immunotherapy
Special Lecture 1: Molecular Mechanisms and Treatment of Hereditary Angioedema (HAE)
2-13: Molecular Mechanisms and Treatment of Hereditary Angioedema (HAE)
2-13: Molecular Mechanisms and Treatment of Hereditary Angioedema (HAE)
WAO Junior Member Session 2029: Practical Course on Immunotherapy
2-16: Current Status and Future Perspectives of Immunotherapy in Latin America and Cuba
2-16: Current Status and Future Perspectives of Immunotherapy in Latin America and Cuba
WAO Junior Member Session 2029: Practical Course on Immunotherapy
2-17: Use of New Technology to Improve Utilization and Adherence to Immunotherapy
2-17: Use of New Technology to Improve Utilization and Adherence to Immunotherapy
WAO & AAAAI Session 2028: Update on Urticaria Guidelines - This session is funded through an educational grant from Genentech
2-18: Overview of Acute and Chronic Urticaria
2-18: Overview of Acute and Chronic Urticaria
WAO & AAAAI Session 2028: Update on Urticaria Guidelines - This session is funded through an educational grant from Genentech
2-19: Chronic Urticaria: New Management Options
2-19: Chronic Urticaria: New Management Options